Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA ® (narsoplimab-wuug), the first and only therapy indicated for ...

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...

(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the ...

Ticks are small, but their saliva is busy. It carries a toolkit of proteins and other molecules that let a tick feed for days while keeping the bite site quiet and easy to tap for blood. In the United ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

The complement system, consisting of three initiating pathways—classical, lectin and alternative, is an important part of innate immunity. Dysregulation of the complement system is implicated in the ...

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system-a group of proteins that ...